Pyrroloquinoline quinone influences intracellular alpha-synuclein aggregates

Elizabeth Mountford, Cynthia Mathew, Reena Ghildyal, Andrea Bugarcic

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)


Parkinson's disease (PD) is an irreversible neurodegenerative disorder clinically manifesting in uncontrolled motor symptoms. There are two primary hallmark features of Parkinson's disease - an irreversible loss of dopaminergic neurons of the substantia nigra pars compacta and formation of intracellular insoluble aggregates called Lewy bodies mostly composed of alpha-synuclein. Using a clinical improvements-first approach, we identified several clinical trials involving consumption of a specific diet or nutritional supplementation that improved motor and nonmotor functions. Here, we aimed to investigate if and how pyrroloquinoline quinone (PQQ) compound disrupts preformed alpha-synuclein deposits using SH-SY5Y cells, widely used Parkinson's disease cellular model. SH-SY5Y neuroblastoma cells, incubated in presence of potassium chloride (KCl) to induce alpha-synuclein protein aggregation, were treated with PQQ for up to 48 hr. Resulting aggregates were examined and quantified using confocal microscopy. Overall, nutritional compound PQQ reduced the average number and overall size of intracellular cytoplasmic alpha-synuclein aggregates in a PD cellular model.

Original languageEnglish
Article numbere12
Pages (from-to)1-13
Number of pages13
JournalExperimental Results
Publication statusPublished - 11 May 2023


Dive into the research topics of 'Pyrroloquinoline quinone influences intracellular alpha-synuclein aggregates'. Together they form a unique fingerprint.

Cite this